Manning Paul's Insider Trades & SAST Disclosures
Manning Paul's most recent trade in Sensient Technologies Corp. was a trade of 26,658 Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Manning Paul.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 26,658 | 266,312 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 26,658 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.00 per share. | 13 Feb 2025 | 13,329 | 252,983 (0%) | 0% | 77 | 1,026,333 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 16 Dec 2024 | 750,000 | 1,303,752 | - | 6 | 4,500,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 16 Dec 2024 | 500,000 | 1,142,406 | - | 6 | 3,000,000 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.00 per share. | 09 Dec 2024 | 8,695 | 239,654 (0%) | 0% | 78 | 678,210 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 34,492 | 34,492 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 22,994 | 248,349 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 18,426,966 | 26,278,094 (101%) | 71% | - | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 9,213,483 | 9,213,483 | - | - | Series A Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 9,213,483 | 9,213,483 | - | - | Series B Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 4,494,382 | 5,976,101 (23%) | 17% | - | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 2,247,191 | 2,247,191 | - | - | Series B Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 2,247,191 | 2,247,191 | - | - | Series A Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Nov 2024 | 450,000 | 25,828,094 (100%) | 1% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 2,675,611 | 0 (0%) | 10% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Liquidia Corp | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 8.90 per share. | 12 Sep 2024 | 337,078 | 816,311 (2%) | 1% | 8.9 | 2,999,994 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 27 Jun 2024 | 1,333,333 | 1,333,333 | - | 2.2 | 2,999,999 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,359 | 299,689 (1%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp. | Manning Paul | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 36,005 | 243,357 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp. | Manning Paul | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 36,005 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.74 per share. | 08 Feb 2024 | 18,002 | 225,355 (0%) | 0% | 62.7 | 1,129,445 | Common Stock |
| Liquidia Corp | Manning Paul B. | Director | Purchase of securities on an exchange or from another person at price $ 7.16 per share. | 14 Dec 2023 | 279,330 | 279,330 (0%) | 0% | 7.2 | 2,000,003 | Common Stock |
| Sensient Technologies Corp. | Manning Paul | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.33 per share. | 11 Dec 2023 | 9,686 | 207,352 (0%) | 0% | 61.3 | 594,042 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 42,442 | 42,442 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Manning Paul | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 28,294 | 217,038 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 16,466,667 | 16,466,667 | - | 0.9 | 14,820,000 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 5.02 per share. | 24 Jul 2023 | 200,000 | 7,851,128 (30%) | 0% | 5.0 | 1,004,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2023 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 100,756 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 100,756 | 239,122 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.49 per share. | 09 Feb 2023 | 50,378 | 188,744 (0%) | 0% | 72.5 | 3,651,901 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 35,160 | 35,160 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 23,440 | 138,366 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 31 Oct 2022 | 1,500,000 | 1,642,202 | - | 2 | 3,000,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2022 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 05 Jul 2022 | 4,761,904 | 13,651,128 (52%) | 18% | 2.1 | 9,999,998 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Liquidia Corp | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 5.10 per share. | 18 Apr 2022 | 392,156 | 392,156 (1%) | 1% | 5.1 | 1,999,996 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 435,674 | 435,674 (1%) | 1% | 0 | Common Stock | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 17,800 | 123,826 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 17,800 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.43 per share. | 10 Feb 2022 | 8,900 | 114,926 (0%) | 0% | 83.4 | 742,527 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 58,000 | 92,202 | - | 7.8 | 450,660 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.84 per share. | 02 Feb 2022 | 50,000 | 142,202 | - | 7.8 | 392,000 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 45,000 | 2,065,102 | - | 7.8 | 349,650 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.84 per share. | 02 Feb 2022 | 26,602 | 2,091,704 | - | 7.8 | 208,560 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 22,000 | 22,000 | - | 7.8 | 170,940 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 26,084 | 26,084 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 17,390 | 106,026 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.45 per share. | 02 Dec 2021 | 30,023 | 8,129,417 (31%) | 0% | 9.4 | 283,717 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.22 per share. | 02 Dec 2021 | 19,977 | 8,149,394 (31%) | 0% | 9.2 | 184,188 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 13.19 per share. | 24 Nov 2021 | 2,202 | 34,202 | - | 13.2 | 29,044 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.54 per share. | 23 Nov 2021 | 20,000 | 32,000 | - | 12.5 | 250,800 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 1,669,303 | 0 | - | - | Series B Preferred Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 29 Jul 2021 | 1,625,000 | 1,681,000 | - | 8 | 13,000,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 1,361,069 | 0 | - | - | Series B Preferred Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 679,158 | 679,158 | - | - | Common Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 553,752 | 553,752 | - | - | Common Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 7.36 per share. | 27 Jul 2021 | 36,000 | 36,000 | - | 7.4 | 264,834 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 7.30 per share. | 27 Jul 2021 | 20,000 | 56,000 | - | 7.3 | 145,944 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.98 per share. | 14 May 2021 | 12,000 | 12,000 | - | 21.0 | 251,760 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.52 per share. | 13 Apr 2021 | 198,413 | 737,646 (2%) | 0% | 2.5 | 500,001 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.75 per share. | 25 Mar 2021 | 739,830 | 739,830 (2%) | 2% | 14.8 | 10,912,493 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 21,385 | 21,385 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 39,100 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 29,059 | 29,059 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 19,373 | 88,636 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 3,275,205 | 3,275,205 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 3,006,155 | 0 | - | - | Series A Preferred Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 2,008,158 | 2,008,158 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 1,843,193 | 0 | - | - | Series A Preferred Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 11,944 | 2,020,102 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | 28 Sep 2020 | 10,963 | 0 | - | - | Series B Preferred Stock | ||
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.09 per share. | 20 Aug 2020 | 20,000 | 8,099,394 (31%) | 0% | 9.1 | 181,800 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.55 per share. | 18 Aug 2020 | 10,000 | 1,481,719 (5%) | 0% | 8.6 | 85,500 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 6.92 per share. | 17 Aug 2020 | 6,000 | 1,471,719 (5%) | 0% | 6.9 | 41,520 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 6.41 per share. | 13 Aug 2020 | 108,500 | 1,415,719 (5%) | 0% | 6.4 | 695,485 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 6.51 per share. | 13 Aug 2020 | 50,000 | 1,465,719 (5%) | 0% | 6.5 | 325,500 | Common Stock |
| Sensient Technologies Corp. | Paul Manning | Director, Chairman, President & CEO | Purchase of securities on an exchange or from another person at price $ 45.85 per share. | 18 May 2020 | 20 | 60 (0%) | 0% | 45.9 | 917 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges